2017 Press Releases Keyword Search Year: 20202019201820172016201520142013 Nov 1, 2018 Summary ToggleAgios to Present Updated Clinical Data at the 2018 ASH Annual Meeting Nov 1, 2018 Summary ToggleAgios Reports Third Quarter 2018 Financial Results Oct 18, 2018 Summary ToggleAgios to Webcast Conference Call of Third Quarter 2018 Financial Results on November 1, 2018 Sep 4, 2018 Summary ToggleAgios Announces Chief Executive Officer Succession Plan Aug 28, 2018 Summary ToggleAgios to Present at the Citi 13th Annual Biotech Conference Wednesday, September 5, 2018 Aug 2, 2018 Summary ToggleAgios Reports Second Quarter 2018 Financial Results Jul 23, 2018 Summary ToggleAgios to Webcast Conference Call of Second Quarter 2018 Financial Results on August 2, 2018 Jul 20, 2018 Summary ToggleFDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation Jun 26, 2018 Summary ToggleAgios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China Jun 18, 2018 Summary ToggleAgios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused Jun 4, 2018 Summary ToggleNew Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients Jun 2, 2018 Summary ToggleUpdated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent Jun 1, 2018 Summary ToggleAgios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors May 16, 2018 Summary ToggleAgios to Present New Clinical Data from its IDH Programs at ASCO May 4, 2018 Summary ToggleAgios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day Apr 27, 2018 Summary ToggleAgios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results Webcast on Friday, May 4, 2018 Apr 11, 2018 Summary ToggleAgios to Webcast Investor Day and First Quarter 2018 Financial Results on Friday, May 4, 2018 Mar 19, 2018 Summary ToggleAgios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion Mar 5, 2018 Summary ToggleAgios to Present at the Cowen 38th Annual Healthcare Conference Monday, March 12, 2018 Feb 15, 2018 Summary ToggleFDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation Feb 14, 2018 Summary ToggleAgios Reports Fourth Quarter and Full Year 2017 Financial Results Jan 31, 2018 Summary ToggleAgios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018 Jan 23, 2018 Summary ToggleAgios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Jan 18, 2018 Summary ToggleAgios Announces Pricing of $475 Million Public Offering of Common Stock Jan 17, 2018 Summary ToggleAgios Announces Proposed Offering of Common Stock Jan 8, 2018 Summary ToggleAgios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value Jan 2, 2018 Summary ToggleAgios to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 Dec 26, 2017 Summary ToggleAgios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation Dec 11, 2017 Summary ToggleData from Phase 1 Studies of Ivosidenib or Enasidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation Dec 11, 2017 Summary ToggleNew Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AML Dec 10, 2017 Summary ToggleAgios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency Dec 5, 2017 Summary ToggleAgios Appoints Jacqualyn Fouse, Ph.D., to the Board of Directors Nov 17, 2017 Summary ToggleAgios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma Nov 1, 2017 Summary ToggleAgios to Present New Data from PKR and IDH Programs at the 2017 ASH Annual Meeting Nov 1, 2017 Summary ToggleAgios Reports Third Quarter 2017 Financial Results Oct 31, 2017 Summary ToggleAgios to Present at the 26th Annual Credit Suisse Healthcare Conference Tuesday, November 7, 2017 Oct 25, 2017 Summary ToggleAgios to Webcast Conference Call of Third Quarter 2017 Financial Results on November 1, 2017 Sep 5, 2017 Summary ToggleAgios to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Monday, September 11, 2017 Aug 8, 2017 Summary ToggleAgios Reports Second Quarter 2017 Financial Results Aug 3, 2017 Summary ToggleAgios to Present at the Canaccord Genuity 37th Annual Growth Conference Thursday, August 10, 2017 Aug 1, 2017 Summary ToggleFDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation Jul 28, 2017 Summary ToggleAgios to Webcast Conference Call of Second Quarter 2017 Financial Results on August 8, 2017 Jun 24, 2017 Summary ToggleNew Data from Phase 1/2 Trial of Oral IDHIFA® (enasidenib) Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML Jun 24, 2017 Summary ToggleAgios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency Jun 6, 2017 Summary ToggleUpdated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last